@article {Mikhail:2011:1567-2018:511,
title = "Quick-Release Bromocriptine for Treatment of Type 2 Diabetes",
journal = "Current Drug Delivery",
parent_itemid = "infobike://ben/cdd",
publishercode ="ben",
year = "2011",
volume = "8",
number = "5",
publication date ="2011-09-01T00:00:00",
pages = "511-516",
itemtype = "ARTICLE",
issn = "1567-2018",
url = "https://www.ingentaconnect.com/content/ben/cdd/2011/00000008/00000005/art00004",
doi = "doi:10.2174/156720111796642255",
keyword = "dizziness, Type 2 diabetes, obesity, hyperprolactinemia, prolactin, diabetes, nausea, hyperglycemia, dopamine agonists, bromocriptine, insulin resistance, circadian rhythm, cabergoline",
author = "Mikhail, Nasser",
abstract = "Quick-release bromocriptine (bromocriptine-QR) (Cycloset) was approved in 2009 for the treatment of type 2 diabetes. The exact anti-diabetic mechanism of action of bromocriptine-QR has not been elucidated, but the drug may help resetting the circadian dopamine signal. Randomized placebo-controlled
trials showed that the mean reduction in hemoglobin A1c (HbA1c) levels by bromocriptine-QR was 0.0-0.2% when compared to baseline and 0.4-0.5% when compared with placebo after 24 weeks of therapy. Withdrawal rates due to adverse effects in patients receiving bromocriptine- QR
and placebo were 24% and 11%, respectively. The most common adverse effect of bromocriptine-QR was nausea reported by 32% of patients compared with 7% of patients randomized to placebo. The advantages of bromocriptine- QR were minimal risk of hypoglycemia, neutral
effect on weight, and reassuring cardiovascular safety over 1 year of use. However, the drug had multiple drawbacks including modest efficacy, high rates of nausea, lack of long-term efficacy and safety data, and considerable cost. Bromocriptine-QR may be used in patients with type 2 diabetes
with mild hyperglycemia (HbA1c close to 7.5%) either as adjunctive treatment to metformin and sulfonylurea (SU) or as monotherapy in patients who are intolerant to both agents. 
",
}